Recent advances in the understanding of the molecular mechanisms of apoptosis has gained increasing interest in the cardiovascular research community. Apoptotic myocyte loss has been detected in different cardiac disease states such as ischemic heart disease and congestive heart failure. In addition, some evidence for the molecular mechanisms in cardiac myocyte apoptosis has been evolving, although at present the implications thereof for clinical cardiac disease are not known in most of the cases. Based on these new insights, it is the intention of this article to highlight some topics in apoptosis research that might be of particular interest to define the future role and potentials of new therapeutic approaches aimed at preventing myocyte apoptosis.
Introduction
cardiovascular disease see [1] ). In contrast to necrotic cell death, initiation and regulation of apoptosis involves The pathophysiology of major cardiac disease states several checks and balances that allow for cell survival such as ischemic heart disease and congestive heart failure even though a death stimulus directly acts on the cell (e.g. is multifactorial. At the level of the myocyte both dysfuncBcl-2 preventing cell death induced by staurosporine). In tion due to altered calcium handling, impaired excitationaddition, cell death has been shown to be amenable to contraction coupling and electrical instability on the one pharmacologic intervention (e.g. caspase inhibition with hand and irreversible myocyte loss on the other hand are zVAD.fmk). However, although promising new results on believed to contribute to disease initiation and progression. myocyte apoptosis have been published in the last few The rationale of current therapy is mainly to modify years, several unresolved issues remain, of which the myocyte dysfunction and to minimize the intensity of the pathophysiologic significance of myocyte, the role of lethal injury acting on the myocyte such as duration of growth factors, mitochondrial mechanisms, death receptor ischemia or the degree of pressure overload. Preservation pathways and cell cycle control appear to be of particular of cells subjected to a lethal injury remains an attractive, interest. but elusive goal. This is mainly due to the notion that once the death-inducing stimulus has reached the myocyte, the cell can no longer evade its demise leaving no room for 2. Significance of myocyte apoptosis regulation or therapeutic intervention.
Recent progress in the study of myocyte apoptosis has Increased interest in apoptosis research in cardiology once again increased interest in modifying myocyte death mainly stems from the hope that understanding the mechaat the cellular level (for a detailed review on apoptosis in nisms of apoptosis in cardiac myocytes may provide new strategies to prevent myocyte loss. A major determinant *Corresponding author. Tel.: 11-617-667-4858; fax: 11-617-975-5268.
Time for primary review 30 days.
for the success of this novel approach is the degree to 3. Trophic signals and survival factors which apoptosis contributes to total myocyte loss and to which extent this additional loss of contractile mass can be Several cell types like lymphoid and neuronal cells prevented to improve functional deterioration and mortality critically depend on growth factors for survival in culture. in cardiac disease.
Deprivation of cells of interleukin-3 or nerve growth factor Current evidence for myocyte apoptosis has mostly been in culture induces extensive apoptosis [12, 13] . Although gathered in isolated cardiac myocytes (both neonatal and initially not appreciated, there is increasing evidence that adult), isolated perfused hearts and in animal models of survival of cardiac myocytes may also depend on the ischemia and pressure-overload [2] [3] [4] [5] [6] [7] . Although isolated presence of survival signals. Cardiotrophin-1 is a member myocyte preparations are well suited to study the apoptotic of the interleukin-6 family of cytokines and exerts a strong potential of a given stimulus and the intracellular mechahypertrophic stimulus on isolated myocytes [14] . nisms involved, one has to be prudent in extrapolating Cardiotrophin-1 has been shown to promote cell survival quantitative analyses to the in vivo situation. Baseline rate of isolated neonatal cardiac myocytes kept under serumof apoptosis is reported to be in the range of 5-10% in free conditions [15] . A similar effect was observed for most studies of cultured myocytes, which exceeds the true leukemia inhibitory factor that signals through a receptor baseline apoptotic rate in heart sections by approximately sharing the gp130 large receptor subunit with the CT-1 1000-fold [8] . Likewise, some stimuli induce apoptosis in receptor [15] . The concept of gp130-dependent cardiopas many as 75% of the cells, which certainly overestimates rotection was recently further substantiated in a cardiacthe true incidence even under pathophysiologic conditions specific knockout of gp130 [16] . While transverse aortic [2, 3] .
banding in wild-type mice induced concentric, compenAlthough studies in isolated perfused hearts, animal sated hypertrophy, gp130-deficient mice exhibited marked models of cardiovascular disease and post-mortem studies biventricular chamber dilation, impaired left ventricular in patients allow for a better estimate of the importance of function and reduced survival. Development of chamber myocyte apoptosis in the setting of cardiac disease, the dilation correlated with a marked increase in apoptosis, reported extent of myocyte apoptosis sometimes varies suggesting that under stress conditions a trophic signal widely. For example, in congestive heart failure the may be essential to maintain myocyte viability. apoptotic index has been reported to range from 0.2 to Likewise, insulin-like growth factor I was shown to 30% [8, 9] . One recent report even questioned the occurreduce myocyte apoptosis in response to myocardial rence of apoptosis in heart failure, relating positive ischemia, ischemia-reperfusion [17, 18] and doxorubicin TUNEL staining to DNA repair and not to apoptotic DNA treatment [19] . However, although the number of apoptotic breakdown [10] . Part of this may be due to differences in myocytes was reduced in the peri-infarct region of IGF-1 the severity of the disease, heterogeneity in tissue sampling transgenic mice, cardiac functional parameters did not or experimental protocols, but further clarification will be differ between transgenic and wild-type mice [18] . Recentof major importance. Furthermore, apoptosis as assessed ly, also the neuregulin group of growth and differentiation by TUNEL staining which implies DNA nicking, may not factors has been implicated in the protection of isolated necessarily represent the cell population that is amenable cardiac myocytes from apoptosis [20] , increasing the list of to rescue by anti-apoptotic therapy, as myocytes might potential inputs that may contribute to the long-term have been damaged irreversibly and inhibition of apoptosis survival of cardiac myocytes. at this stage would just alter the modality of cell death, but However, some questions still remain unanswered. Does would not prevent myocyte loss.
signaling through gp130 and the receptors for IGF-1 and Only a few reports provide evidence for the potential of neuregulin converge on the same point of the apoptotic anti-apoptotic therapy to improve outcome in cardiac cascade or does it affect different targets? For example, disease. In a rat model of ischemia and reperfusion, Yaoita different anti-apoptotic strategies of different trophic facet al. showed that caspase inhibition reduced infarct size tors might include the possibility of an additive antiand improved cardiac function [11] . However, the observaapoptotic effect. Furthermore, if protection interferes with tion period of this study was limited to 24 h and it remains upstream events of apoptotic myocyte death and not with to be shown whether the beneficial effect observed will last common downstream pathways (e.g. caspases), the protecfor an extended follow-up period. One major focus of tive effect of certain survival factors may depend on the future research should therefore be directed not only at stimulus that induces apoptosis. verifying apoptosis in certain disease conditions, but at Current evidence suggests that insulin-like growth factor providing evidence that inhibition of apoptotic myocyte I activates phosphatidylinositol-3 kinase (PI-3K) [21] . loss translates into a long-term benefit in terms of cardiac Through activation of the downstream kinase Akt (also function and / or survival. This will help to outline the known as protein kinase B) the pro-apoptotic regulator treatment potential of anti-apoptotic therapy in heart Bad is phosphorylated and neutralized through cytosolic disease.
sequestration [22] . Nevertheless, signaling through PI-3K may be more complex and may involve additional anticaspase-9 and (d)ATP that finally leads to the activation of apoptotic mechanisms. In contrast, the anti-apoptotic sigcaspase-9 and of the downstream caspase-3 [31] . The naling of gp130 was shown to involve the MEK1 / ERK second pathway is initiated by the opening of the perpathway of mitogen-activated protein kinases [15] . Howmeability transition pore, release of apoptosis-inducing ever, ERK activation may not be enough to determine the factor (AIF) and the induction of apoptotic changes of the anti-apoptotic characteristic of cardiotrophin-1, as other nucleus and the cell membrane [32] . At present, it is not receptor ligands that activate ERK (like angiotensin II) do known how these pathways are related to each other, and not protect against apoptosis [23] . Concomitant activation whether the apoptotic pathway is dependent on the type of of other signaling pathways or failure to do so may death stimulus. Of importance, the AIF pathway is cascritically influence the role of ERK activation. In this pase-independent and thus can only be inhibited by Bcl-2, regard, it will be of major interest to further define the role but not by caspase inhibition [32] . of other mitogen-activated protein kinase such as JNK and Little is known in how far this applies to apoptosis in p38 which have been implicated in the regulation of cardiac myocytes. Myocytes are permanently performing a apoptosis in isolated cardiac myocytes [24, 25] . A better huge mechanical work load that is fueled by oxidative understanding of the downstream targets of MAPK casphosphorylation of glucose, fatty acids and ketone bodies. cades may elucidate additional regulatory mechanisms in Consequently, mitochondria make up a substantial propormyocyte apoptosis.
tion of total cellular volume. This may put cardiac In addition, the role of intercellular contact and cellmyocytes at increased risk of involuntary induction of matrix interaction in myocyte survival is not well underapoptosis, as turnover of mitochondria may cause leakage stood. For myocyte isolation, culture dishes need to be of pro-apoptotic mitochondrial contents into the cytosol. In coated either with gelatin or laminin to allow for cell addition, short-term ischemia and cardioplegia during adherence. Failure to adhere inevitably leads to cell death cardiac surgery can induce morphological alterations in (anoikis) [26] . Multiple cell-matrix interactions involving myocyte mitochondria at an early stage [33] . To counteract focal adhesions or integrins are known in cardiac myocytes this permanent threat myocytes might have evolved [27, 28] . These are linked to intracellular signaling cascades specialized anti-apoptotic strategies, either by rendering and may thus be capable of regulating both pro-apoptotic mitochondria less pro-apoptotic or by expressing powerful and anti-apoptotic signals.
anti-apoptotic safeguards. Initial attempts have been made to introduce growth Myocytes are known to express Bcl-2 and Bcl-x and factors as a new treatment modality into clinical practice.
overexpression of Bcl-2 in isolated neonatal rat ventricular A preliminary study of human growth hormone, which myocytes can inhibit apoptosis induced by overexpression increases serum levels of IGF-1, in patients with dilated of p53, which is believed to involve mitochondria [34] . cardiomyopathy showed increased cardiac performance However, given the abundance of mitochondria in cardiac and exercise capacity after 3 months of treatment, although myocytes, baseline expression of Bcl-2 is low compared to it is not known whether apoptotic myocyte loss was other cell lineages such as lymphoid cells. And, mice reduced in these patients [29] . However, in a more recent deficient in Bcl-2 were not reported to exhibit an increased study only myocardial hypertrophy was observed, but no rate of apoptosis of cardiac myocytes or cardiac failure functional improvement could be documented after 3 [35, 36] . Alternatively, endogenous inhibitors of caspases months [30] . Both studies included only a small number of like IAP-1 or XIAP might neutralize low-level caspase patients and the observation period was short. Further activation and, unless overwhelmed by massive cytoanimal and clinical studies are required to substantiate chrome c release from mitochondria, effectively prevent treatment benefits of this novel therapeutic approach in inadvertent apoptosis. It will be of interest to see whether cardiac disease.
inactivation of endogenous caspase inhibitors (IAP-1, XIAP) [37, 38] will affect baseline apoptotic rate in cardiac myocytes and whether this will lead to deterioration of 4. Mechanisms of myocyte apoptosis mediated by cardiac function. mitochondria A recent observation in primary cultures of sympathetic neurons adds to the complexity of regulatory mechanisms With the localization of the apoptotic regulatory proteins involved in apoptosis. Deprivation of these cells of nerve of the Bcl-2 family to mitochondria and the demonstration growth factor (NGF) induces delayed apoptosis (.18 h) that isolated mitochondria can exert a pro-apoptotic effect that is dependent on Bax and involves protein synthesis in in vitro model systems, mitochondrial involvement in and cytochrome c release from mitochondria [39] . Surprisapoptosis has gained increasing interest. Currently, two ingly, microinjection of cytochrome c into the cytosol did mechanisms have been described relating mitochondria to not induce apoptosis in cells kept with NGF. Only when the induction of apoptosis. One involves the release of cells were deprived of NGF (and kept alive by inhibition of cytochrome c, formation of a complex with apaf-1, protein synthesis or due to Bax deficiency) did they undergo apoptosis in response to cytochrome c injection, activation of death receptors. Therefore, expression or indicating that NGF withdrawal induces apoptosis by stimulation of death receptors might not be sufficient to affecting two checkpoints in one pathway: one regulating induce myocyte apoptosis as long as these anti-apoptotic the barrier function of the outer mitochondrial membrane mechanisms are still in place. A two-step hypothesis of and an additional one that prevents apoptosis downstream myocyte apoptosis in response to death receptor stimulaof cytochrome c release, the nature of which is not well tion may be postulated, that requires both death receptor understood. The susceptibility of cardiac myocytes to activation and concomitant relief of the post-receptor block microinjected cytochrome c and the concentration of of apoptosis. This may be an important safeguard of a cell cytochrome c necessary to induce myocyte apoptosis are type that, on the one hand, has lost its regenerative not known, but it would be of major interest to detect capacity and, on the other hand, expresses efficient proadditional anti-apoptotic mechanisms that lie downstream apoptotic mechanisms. Future studies should therefore of mitochondrial damage and that are amenable to regulaanalyze both the pro-apoptotic and anti-apoptotic contion.
stituents of the death receptor pathway. Additional and very intriguing evidence for the importance of death receptors and especially FADD and caspase-5. Death receptors 8 in the heart comes from observations in knockout mice. Mice deficient in either FADD or caspase-8 exhibit thinned Stimulation of a group of cell surface receptors of the myocardium, reduced myocardial trabeculations and intumor necrosis factor receptor family induces apoptosis in trauterine death at around day 10-13 [53, 54] . Neither Fas several cell types such as hepatocytes or the lymphoid deficiency, nor deficiency of TNFR1 induces a similar Jurkat cell line. Death receptor / ligand combinations incardiac phenotype during development [55] [56] [57] . At presclude Fas / Fas ligand, TNFR1 / TNF-a, death receptor (DR) ent, it is not known which receptor pathway is upstream of 3 / DR3 ligand and the death receptors 4 and 5, which both FADD and caspase-8 activation during cardiac developbind the ligand TRAIL [40] . In the case of Fas, TNFR1 ment. It also remains to be established whether the cardiac and DR3 downstream signaling involves the adaptor phenotype is due to FADD and caspase-8 deficiency in protein FADD and caspase-8, which activates the excardiac myocytes or another cell lineage such as endotheliecutioner caspases-3 and -7, while intracellular signaling al cells. Furthermore, during development FADD and of DR4 and DR5 has not yet been characterized in detail.
caspase-8 may not necessarily be involved in pro-apoptotic At least expression of Fas, TNFR1, DR4 and DR5 has signaling, as at least FADD has a role in signal pathways been documented either at the protein or mRNA level in not related to apoptosis [58] . In a recent study in mice, cardiac myocytes [41-44]. During ischemia or hypoxia overexpressing a dominant-negative mutant of FADD expression of Fas was increased and correlated with the under the control of a lymphocyte-specific promoter, both induction of apoptosis [6, 42, 45] . In addition, myocardial thymocytes and peripheral T cells exhibited an abnormal concentrations of TNF-a, the ligand for TNFR1, were proliferative response to stimulation of CD3 and CD28 increased during ischemia and after stimulation with [58] . Clearly, further studies are required to delineate the lipopolysaccharide [46, 47] .
role of death receptors, FADD and caspase-8 during However, despite all these observations suggestive for cardiac development. Stimulation of death receptors might death receptor-mediated apoptosis of cardiac myocytes, constitute an important mechanism that allows for the direct evidence for apoptosis in response to death receptor cross-talk between different cell lineages to adjust relative activation is scant and limited to cell culture studies [48] .
cell numbers and promote differentiation. So far, most observations indicate a strong negative inotropic effect for TNF-a [49] , while Fas stimulation appears to affect action potential and calcium handling 6. Cell cycle regulation and myocyte apoptosis [50] . One explanation for this might be that cardiac myocytes, in addition to the expression of pro-apoptotic Acute or progressive myocyte loss leads to cardiac constituents of the death receptor pathways, also show functional deterioration, once loss of contractile tissue is strong expression of the anti-apoptotic mechanisms that no longer compensated by functional reserve. As myocytes control apoptosis in response to death receptor agonists.
have no or at least an insufficient replicative capacity to This includes the expression of decoy receptors for TRAIL replace cell losses [59, 60] , it has been a challenge to like TRID [43] , which lacks the intracellular domains disentangle the mechanisms that keep myocytes arrested in essential for signaling, and FLAME-1 and ARC [51, 52] , the G0 / G1 phase of the cell cycle. Cell proliferation which interfere with caspase-8 activation and its encompasses replication of genomic DNA, mitotic nuclear proteolytic activity, respectively. The almost exclusive division and cytokinesis, all of which are regulated by expression of ARC in skeletal and cardiac muscle further effective checkpoint controls. A major mechanism of G1 / supports an important role of anti-apoptotic mechanisms in S phase control is based on the phosphorylation of the cells of the myocyte lineage that counterbalance the retinoblastoma gene product by a complex of cyclin-dependent kinases and cyclin D, which results in the Of even greater importance is to define the implications release and thus activation of the positive cell cycle of myocyte apoptosis and its extent to the progression of regulator E2F. However, when E2F-1 or the adenoviral cardiac disease, as this will delineate the potentials of an protein E1A are overexpressed in isolated neonatal rat anti-apoptotic strategy in cardiac disease states. Almost all cardiac myocytes or in adult mouse myocardial tissue, cell studies on apoptosis in patients and in animal models of cycle progression is associated with myocyte apoptosis cardiac disease are descriptive verifying the presence of [61] [62] [63] . Are therefore cell cycle progression and apopapoptotic cells, while the relation of apoptosis of myocytes tosis linked inextricably, providing a safeguard against to functional outcome remains mostly unknown. Unforuncontrolled proliferation? Not necessarily, as evidenced tunately, the number of studies using an interventional by the fact that overexpression of cyclin D1 in cardiac approach in in vivo models of cardiac disease are still myocytes results in the generation of multinucleate cardiac limited [11, 16] . myocytes, which must have past both the G1 / S and G2 / M In summary, substantial evidence has accumulated that checkpoints [64] . Furthermore, in a fibroblast cell line, apoptosis is a component of clinical cardiac disease states contrary to E2F-1, overexpresssion of E2F-2 and E2F-3 of major epidemiologic importance. However, future reallowed for the dissociation of cell proliferation from search will have to better define pathologic and molecular apoptosis [65] . Nevertheless, a better understanding of the criteria to verify the occurrence and extent of apoptosis of relationship between cell cycle control and apoptosis in cardiac myocytes with greater sensitivity and especially cardiac myocytes will be necessary for the pursuit of specificity. In addition, more studies are required to strategies to induce myocyte proliferation in vitro and in provide evidence for the pathophysiologic significance of vivo.
apoptosis for organ dysfunction and clinical outcome, in order to further substantiate current hopes that apoptosis of myocytes will become a new target for future therapeutic 7. Conclusion intervention.
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